This company has been acquired
Chembio Diagnostics Balance Sheet Health
Financial Health criteria checks 5/6
Chembio Diagnostics has a total shareholder equity of $17.8M and total debt of $18.6M, which brings its debt-to-equity ratio to 104.4%. Its total assets and total liabilities are $62.6M and $44.8M respectively.
Key information
104.4%
Debt to equity ratio
US$18.59m
Debt
| Interest coverage ratio | n/a |
| Cash | US$18.18m |
| Equity | US$17.80m |
| Total liabilities | US$44.81m |
| Total assets | US$62.61m |
Recent financial health updates
Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02Financial Position Analysis
Short Term Liabilities: CEMI's short term assets ($48.5M) exceed its short term liabilities ($39.3M).
Long Term Liabilities: CEMI's short term assets ($48.5M) exceed its long term liabilities ($5.5M).
Debt to Equity History and Analysis
Debt Level: CEMI's net debt to equity ratio (2.3%) is considered satisfactory.
Reducing Debt: CEMI's debt to equity ratio has increased from 0.8% to 104.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CEMI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CEMI has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 23% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 02:20 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chembio Diagnostics, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Raymond Myers | Benchmark Company |
| Mark Massaro | Canaccord Genuity |